Company Overview of Histogenics Corporation
Peter S. Greenleaf
Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee, Sucampo Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 2 Board Members in 2 different organizations across 7 different industries.|
See Board Relationships
830 Winter StreetPhone: 781-547-7900
Waltham, Massachusetts 02451
Board Members Memberships
Former Chief Executive Officer and Director
Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Saint Joseph's University
Western Connecticut State University
Annual CompensationThere is no Annual Compensation data available.
Stocks OptionsThere is no Stock Options data available.
Total CompensationThere is no Total Compensation data available.
|Michael W. Aguiar||Chief Executive Officer, President and Director|
|Mark R. Baker J.D.||Chief Executive Officer, Director and Member of Science & Strategy Committee|
Progenics Pharmaceuticals, Inc.
|A. J. Kazimi MBA||Founder, Chairman, Chief Executive Officer and President|
Cumberland Pharmaceuticals, Inc.
|Douglas L. Drysdale||Chairman, Chief Executive Officer and President|
Pernix Therapeutics Holdings, Inc.
|Jeffrey M. Yordon||Founder, Chairman and Chief Executive Officer|
Sagent Pharmaceuticals, Inc.
|$615.2K||Compensation as of Fiscal Year 2013.|